H
uman melanoma cells bear antigens that are recognized CD8 + be derived eiby autologous CTL, which can ther from blood lymphocytes or from tumor-infiltrating lymphocytes (1) . Two distinct strategies have been used to characterize these antigens. The first is a genetic approach based on transfection of genomic or cDNA libraries to identify the gene encoding the antigen (2-7). The antigenic peptide can then be identified on the basis of the protein sequence encoded by the gene (6, (8) (9) (10) (11) (12) . The second approach involves acid elution of peptides from immunoprecipitated HLA molecules followed by separation of the peptides, evaluation of their ability to sensitize target cells to CTL, and sequencing of the active peptide (13, 14) .
A first class of antigens that are recognized on melanoma by autologous CTL is encoded by genes that are expressed in various tumors but that are completely silent in normal adult tissues, except the testis. These genes include genes MAGE-1, MAGE-3, and BAGE (2, 6, 9, 11, 15) . The mouse gene P/A, which codes for a tumor rejection antigen of mouse tumor P815, follows the same pattern of expression (16) . The tumor specificity of these antigens may make them targets of choice for cancer immunotherapy based on specific immunization.
A second class of antigens represents differentiation antigens encoded by genes that are expressed in melanoma and in normal mdanocytes. Antigens derived from tyrosinase were the first examples of this class, which also comprises antigens encoded by Melan-A ~ART-1, gplOOmet17, and gp75 TRPI (3, 4, 7, 10, 12, 13, 17, 18) .
We report here the identification of a new member of the first class of tumor antigens.
MEL.3.1 cells (20) . Lymphoblastoid cell lines MZ2-EBV and LB33-EBV were derived from the PBL of patients MZ2 and LB33 by standard techniques. IGR3-MEL, a melanoma line derived from an HLA-Cw6 patient (22) , was kindly provided by Dr. D. Rimoldi (Ludwig Institute for Cancer Research, Lausanne, Switzerland). HeLa-S3 cells were obtained from the American Type Culture Collection. They were cotransfected by the calcium phosphate precipitate method with the GAGE.1 cDNA cloned in plasmid PeDNA3 (InVitrogen, San Diego, CA), which contains the neomycin resistance gene, and with the HLA-Cw*0601 cDNA cloned in plasmid pcDNAI/Amp (InVitrogen). A clonal subline was isolated from a G418-resistant transfected population.
Lysis Test. Lytic activity of CTL was tested in chromium release assays as previously described (23) . We used indifferently as positive control target MZ2-MEL.43 (see Fig. 1 ) or MZ2-MEL.3.1 (see Fig. 6 ). Negative control target was MZ2-MEL. 4 . Construction of the cDNA Library. Poly-A + RNA was extracted from MZ2-MEL.43 cells using mRNA extraction kit FasTrack (InVitrogen). mRNA was converted to cDNA with the Superscript Choice System (GIBCO BILL, Gaitbersburg, MD) using an oligodT primer containing a NotI site at its 5' end. cDNA were then ligated to BstXI adaptors and digested with NotI. After size fractionation, the cDNA were unidirectionally cloned into the BstXI and NotI sites of plasmid pcDNAI/Amp. Recombinant plasmids were electroporated into Escherichia coli DH5-c~ and selected with ampicillin (50/~g/ml). The library was divided into 1,500 pools of'~100 cDNA clones. Each pool of bacteria was amplified to saturation, and plasmid DNA was extracted by a simplified alkaline lysis method without phenol extraction (24) .
Transfection of COS-7 Cells. Transfection experiments were per-
formed by the DEAE-dextran-chloroquine method (3, 4, 25 were produced with the Erase-a-Base System (Promega) as described (11) . A minigene containing the first 118 nucleotides of GAGE-1 was constructed by PCK using specific primers and was cloned in plasmid pcDNA3. Antigenic Peptides and CTL Assay. Peptides were synthesized on solid phase using F-moc for transient NH2-terminal protection, as described by Atherton et al., and they were characterized by mass spectrometry (32) . All peptides were >90% pure as indicated by analytical HPLC. Lyophilized peptides were dissolved at 20 mg/ml in DMSO, diluted at 2 mg/ml in 10 mM acetic acid, and stored at -80~ Peptides were tested in CTL stimulation assays with COS-7 cells transfected with HLA-Cw*0601 and incubated with the peptides. They were also tested in chromium release assays, where 1,000 SlCr-labeled target cells were incubated for 30 min at 37~ in 96-well microplates with various concentrations of peptide before addition of CTL 76/6 at a lymphocyte/target ratio of 10:1.
The assay was terminated after a 4-h incubation at 37~
l~esu|t$ A panel of stable autologous CTL clones was obtained against the human melanoma cell line MZ2-MEL by stim-ulating PBL from patient MZ2 with irradiated autologous tumor cells (19) . Tumor cell variants selected in vitro for resistance to some of these CTL clones remained sensitive to others, indicating that several different antigens were present on the MZ2-MEL cells (20) . One of these antigens, named MZ2-F, was recognized by CD8 + CTL done 76/6, which lysed autologous MZ2-MEL cells, but neither autologous EBV-B cells nor NK target K562 cells (Fig. 1 ). Upon contact with MZ2 melanoma cells, this CTL clone released TNF, and this was inhibited by an mAb directed against HLA class I molecules (Fig. 2) .
Identification of a eDNA Encoding Antigen MZ2-E To clone the gene encoding antigen MZ2-F, we used KNA from MZ2-MEL to prepare a eDNA library with plasmid pcDNAI/Amp. This plasmid contains the origin of replication of SV40 resulting in considerable episomal multiplication in COS-7 cells and therefore high expression of doned genes (25) . To allow presentation of the antigen to CTL, COS cells must express the appropriate HLA molecule, and this can be achieved by cotransfection of the relevant gene (3, 4) . A prerequisite for this method is therefore the knowledge of the restricting MHC molecule. For antigen MZ2-F, only three of the six HLA class I specificities of patient MZ2, namely A1, B37, and Cw*0601, were possible candidates. This came from the finding that subline MZ2-MEL.3.1, which had lost the HLA-A29, B'4403, and Cw'1601 genes, was still lysed by CTL 76/6 (6, 11, 20) .
The library was divided into pools of 100 recombinant clones, and DNA from each pool was cotransfected into microcultures of COS-7 cells with either the HLA-A1 gene, the HLA-B37 eDNA, or the HLA-Cw*060I eDNA cloned in pcDNAI/Amp. 48 h later, we screened the transfectants for the expression of antigen MZ2-F by adding CTL 76/6 to the microcukures and by measuring TNF production after 18 h. One out of the 500 cDNA pools that were tested proved positive when cotransfected with HLA-Cw*0601. By subdoning the bacteria of this pool and repeating the transfection and screening procedures outlined above with individual plasmid DNA, we obtained several clones that transferred the expression of the antigen. The result obtained with rep- resentative cDNA clone 2D6 is shown in Fig. 2 . When this done was cotransfected into HeLa cells with the HLACw*0601 cDNA, it produced stable transfectants that were also recognized by CTL 76/6 (Fig. 2) . This eDNA was 650 bp long and appeared to be full length, since it hybridized with a similarly sized band on a Northern blot prepared with KNA from MZ2-MEL (Fig. 3) . Its sequence did not show significant homology with any gene reported in data banks, and this new gene was named GAGE.
It contained an open reading frame coding for a protein of 138 amino adds.
The expression of gene GAGE was analyzed by Northern blot with RNA from various tissues. No GAGE mRNA was detected in the normal tissues that were tested, but it was found in a number of mdanoma lines derived from different patients (Fig. 3) . It appeared therefore that expression of antigen MZ2-F results from the activation in mdanoma ceils of a gene that is silent in normal tissues.
The GAGE Gene Family. By hybridizing 5,000 dones of the MZ2-MEL eDNA library with the GAGE eDNA, we obtained 20 other eDNA dones carrying five new homologous sequences that were 80-98% identical to the GAGE eDNA. Accordingly, we renamed GAGE-I the gene corresponding to our first eDNA and named the homologous sequences GAGE-2-6. An alignment of the six eDNA sequences is shown in Fig. 4 . They differ mainly by single nucleotide substitutions scattered throughout the sequence. This lea- HeLa + HLA-Cw6 + cDNA 2D6 ture makes it unlikely that the different CAGE cDNA result from alternative splidng of distinct exons of a single gene, but some of them could correspond to different alleles of the same gene, so that the actual number of GAGE genes may not exceed 3. As shown in Fig. 4 , a sequence of 143 nudeotides that is located near the termination codon of the GAGE-1 coding sequence is absent in the other GAGE cDNA. Because of this insertion, the GAGE-1 putative protein is 20-22 amino acids longer than the five other predicted proteins (Fig. 5) . The first 35 bases of this stretch (nudeotide 376-410) show significant homologies with Alu repeats, and could therefore result from the lack of splidng of an intron (33). However, the sequence of a genomic GAGE done suggests that the GAGE-1 stretch rather corresponds to an additional exon that is homologous to a small region of an intron of the other GAGE genes. A similar situation has been observed with the genes MACE-1 and MACE-2 (34). two overlapping nonamers, namely TYRPRPRRY and YRPRPRRYV, were positive. We then synthesized the octameric peptide common to the two nonamers and the decameric peptide containing both. The four peptides were compared for their ability to sensitize HLA-Cw*0601 + EBV lymphoblastoid cells to lysis by CTL 76/6 (Fig. 6 ). Octamer YRPRPRRY was found to be the optimal peptide. Half maximal lysis was obtained at a peptide concentration of ,o100 nM. The two nonamers were one order of magnitude less efficient and the decamer was even less efficient. Another anti-MZ2-F CTL clone derived from a different blood sample of patient MZ2 also lysed HLA-Cw*0601 + lymphoblastoid cells pulsed with peptide YKPRPRKY (data not shown).
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The gene GAGE-2 codes for the same antigenic peptide as GAGE-l, but the homologous peptides encoded by GAGE-3-6 have tryptophan instead of arginine in position 2 (Fig.  5) . When transfected into COS-7 cells with the HLACw*060I cDNA, only GAGE-1 and GAGE-2 cDNA were able to confer recognition by CTL 76/6, showing that the arginine in position 2 is an essential element of the MZ2-F antigenic peptide (Fig. 7) . 9 of the 21 GAGE cDNA were either GAGE-1 or GAGE-2 sequences.
Expression of GAGE Genes. The expression of the GAGE genes was tested in a panel of normal tissues by reverse transcription PCR (RT-PCK) 1 using primers common to the six GAGE sequences. We found no expression in any normal adult tissue except testis (Table 1) . With another set of primers that amplified only GAGE-I and GAGE.2, we found that a significant proportion of tumors of various histological types express at least one of these genes ( Table 1 ). The highest proportions of positive tumors were found among sarcomas (25%), melanomas (24%), non-small cell lung carcinomas (19%), head and neck tumors (19%), and testicular seminomas (five out of six), but the genes are also expressed in bladder tumors and breast tumors. No expression was found in colorectal carcinomas and renal cell carcinomas. Melanoma line IGR3-MEL, which expresses GAGE-I~2 and HLA-Cw6, triggered TNF release by CTL 76/6 (data not shown) and was lysed by it (Fig. 1) .
Discussion
Two members of the GAGE gene family, GAGE-1 and GAGE-2, code for a tumor-specific antigenic peptide presented to CTL by HLA-Cw*0601. Previous results obtained with mouse tumors revealed two mechanisms that can produce such antigens. One is the occurrence of a point mutation (35) (36) (37) ; the other is the activation in the tumor of a gene that is silent in normal cells (16) . For GAGE, all our evidence supports the second mechanism. GAGE genes are expressed in a number of tumors, but not in normal tissues, except the testis. Furthermore, the fact that two distinct ' Abbreviation used i, this paper: RT-PCR, reverse transcription PCR. members of the GAGE gene family code for this antigen rules out the possibility that the antigen appeared by mutation. Because of its specific expression in tumors, the GAGE antigen may constitute a useful target for specific cancer immunotherapy. The expression of GAGE genes in testis, however, raises the issue of undesirable auto-immune effects. The 
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Van den Eynde 3/6 1/6 0/6 0/6 * Expression of genes GAGE-I-6 was tested by RT-PCR on total RNA with sense primer VDE43 and antisense primer VDE24 (Fig. 4) . These primers are common to the six GAGE sequences. They are located in different exons and amplify a 201-base product that is not observed when genomic DNA is tested.
* Expression of genes GAGE-l-6 was tested by RT-PCR on total RNA with sense primer VDE18 and antisense primer VDE24 (Fig. 4) . These primers amplify the six GAGE sequences. They are located in different exons and give a 239-bp product that is not observed when genomic DNA is tested. s Expression of GAGE-l~2 was tested by RT-PCR on total RNA with sense primer VDE44 and antisense primer VDE24 (Fig. 4) . These primers amplify GAGE-I and GAGE-2, but not GAGE-3-6. They are located in different exons and give a 244-bp product that is not observed when genomic DNA is tested. II NSCLC, non-small cell lung carcinoma. I Fetal tissues derived from fetuses older than 20 w. "" SCLC, small cell lung carcinoma.
testis is an immunoprivileged site, however, and germ-line cells do not express MHC class I molecules and therefore should not express antigens recognized by T cells (38, 39) . In male mice, it was possible to generate CTL responses against a tumor antigen encoded by gene PIA, which is also expressed in testis but not in other normal tissues. We observed neither inflammation of testicular tissues nor reduction of fertility (Uyttenhove, C., B. Leth6, T. Boon, and B. Van den Eynde, manuscript in preparation). In our view, it is therefore likely, but not certain, that immunization against the GAGE antigen will not produce autoimmune effects.
Tumors expressing GAGE-l~2 and HLA-Cw6 can be identified by typing patients for HLA and by testing the expression of GAGE-l~2 by RT-PCK amplification on KNA from a small tumor sample. Because HLA-Cw*0601 is present in 16% of Caucasian individuals and 24% of melanomas express GAGE-I or GAGE-2, ,,04% of all melanomas should express this antigen. This brings to "~51% the fraction of Caucasian melanoma patients eligible for immunotherapy directed against defined tumor antigens encoded by genes MAGE-1, MAGE-3, BAGE, or GAGE ( Table 2 ). The histological distribution of GAGE-positive tumors is rather similar to that of MAGE-1-or MAGE-3-positive tumors. In view of the very high incidence of non-small cell lung cancer, it is noteworthy that 49% of these cancers express at least one of the MAGE-I, MAGE-3, BAGE, GAGE-l, or GAGE-2 genes (40). Accordingly, patients with lung cancer represent the largest cohort of patients that could benefit from specific immunotherapy directed against antigens encoded by these genes.
Melanoma lines studied in vitro were found to simultaneously express several antigens recognized by CTL (20, 41, 42) . Many tumors expressing GAGE-l~2 also express MAGE-1, MAGE-3, or BAGE (data not shown). Some of the patients bearing such tumors could therefore be immunized simultaneously against several antigens encoded by these genes. This might ensure a more effective tumor rejection response.
It should also reduce the emergence of antigen loss variants arising by loss of antigen expression, since it is unlikely that tumor cells could simultaneously delete or mutate several of these genes or lose their expression. Nevertheless, the simultaneous loss of several antigens could still occur after the loss of MHC class I molecules. Fortunately, MHC-negative variants appear to be highly sensitive to NK cells, which may eliminate these variants (43, 44) . In support of this notion, Levitsky et al. observed the very frequent emergence of MHCnegative variants in immunized mice that had been depleted of NK1 + cells before challenge with tumor cells. These variants were less frequently observed in mice that had not been NK depleted (45) .
To the best of our knowledge, the GAGE peptide is the first antigenic peptide presented by HLA-Cw6 that has been identified. A consensus motif for binding to HLA-Cw6 was proposed by Falk et al. on the basis of peptide elution studies (46) . A dominant residue of this motif was L at position 9. Strong residues were P in position 4, I or L in position 5, and V, I, or L in position 6. Our peptide does not fit this motif. A first difference is the presence of tyrosine instead of leucine at the COOH terminus of the GAGE peptide. Although tyrosine was also detected at position 9 in the pool of eluted peptides, it was not considered a dominant or strong residue. Another difference is the fact that the GAGE peptide that is most effective in vitro is an octamer rather than a nonamer, but this does not prove that the octamer is the natural peptide. The cells used by Falk et al. (46) for the peptide elution expressed the HLA-Cw*0602 allele, which was first reported to be distinct from Cw*0601 (47) . However, after correction of sequence uncertainties, the two Cw6 sequences proved identical (48) . In any case, allelic diversity could not explain the divergence of the GAGE peptide from the proposed motif because the cells used by Falk et al. (46) can present the GAGE peptide to CTL 76/6 (data not shown).
Among the class I binding antigenic peptides that have so far been identified in humans, most are presented by HLA-A Corrected* total of melanomas expressing at least one antigen: 51% " The frequency of each HLA specificity in Caucasians is indicated in parentheses. After correction for melanomas expressing both HLA-A1 and HLA-A2, and for melanomas expressing both MAGE-1 and MAGE-3.
